Literature DB >> 16091224

Antiretroviral therapy: when and what to start-- an American perspective.

Timothy J Wilkin1, Roy M Gulick.   

Abstract

The major US treatment guidelines now recommend starting antiretroviral therapy (ART) later in the course of HIV infection because of an increasing awareness of the difficulties associated with these regimens. Most of the data to support this change come from observational cohort studies. When deciding to start ART, several patient-specific factors and other issues should be considered. Because of the many choices for initial ART, clinicians should individualize the choice, taking into account regimen antiretroviral potency, durability, side effects, toxicities, and convenience to ensure a sustained clinical benefit for the patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091224     DOI: 10.1007/s11904-004-0009-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.495


  30 in total

1.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

2.  Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia.

Authors:  Scott F Sieg; Jonathan B Mitchem; Douglas A Bazdar; Michael M Lederman
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

3.  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Authors:  Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

4.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

5.  Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l.

Authors:  Milos Opravil; Bruno Ledergerber; Hansjakob Furrer; Bernard Hirschel; Alexander Imhof; Serge Gallant; Thomas Wagels; Enos Bernasconi; Fabian Meienberg; Martin Rickenbach; Rainer Weber
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

6.  Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.

Authors:  Roy M Gulick; Anne Meibohm; Diane Havlir; Joseph J Eron; Audrey Mosley; Jeffrey A Chodakewitz; Robin Isaacs; Charles Gonzalez; Deborah McMahon; Douglas D Richman; Michael Robertson; John W Mellors
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

Review 7.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

8.  The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Authors:  Amalia Rodriguez-French; Jack Boghossian; Glenda E Gray; Jeffrey P Nadler; Arnaldo R Quinones; Gladys E Sepulveda; Judith M Millard; Paul G Wannamaker
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

9.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Authors:  Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

10.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.

Authors:  J Phair; A Muñoz; R Detels; R Kaslow; C Rinaldo; A Saah
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.